Clinical Trials Browser

Withdrawn × brigatinib × CNS × Clear all

NCT03868423 2022-02-18

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Phase 2 Withdrawn

Brain Neoplasms, Neoplasm Metastasis